156 related articles for article (PubMed ID: 25972739)
1. Ehrlich tumor inhibition using doxorubicin containing liposomes.
Elbialy NS; Mady MM
Saudi Pharm J; 2015 Apr; 23(2):182-7. PubMed ID: 25972739
[TBL] [Abstract][Full Text] [Related]
2. Tuftsin-Bearing Liposomes Co-Encapsulated with Doxorubicin and Curcumin Efficiently Inhibit EAC Tumor Growth in Mice.
Murugesan K; Srinivasan P; Mahadeva R; Gupta CM; Haq W
Int J Nanomedicine; 2020; 15():10547-10559. PubMed ID: 33414637
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Ehrlich tumor inhibition using DOX-NP and gold nanoparticles loaded liposomes.
Mady MM; Al-Shaikh FH; Al-Farhan FF; Aly AA; Al-Mohanna MA; Ghannam MM
Pak J Pharm Sci; 2015 Nov; 28(6 Suppl):2321-5. PubMed ID: 26687750
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
5. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin.
Krishna R; St-Louis M; Mayer LD
Int J Cancer; 2000 Jan; 85(1):131-41. PubMed ID: 10585596
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.
Huang SK; Mayhew E; Gilani S; Lasic DD; Martin FJ; Papahadjopoulos D
Cancer Res; 1992 Dec; 52(24):6774-81. PubMed ID: 1458465
[TBL] [Abstract][Full Text] [Related]
7. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
[TBL] [Abstract][Full Text] [Related]
8. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
9. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
[TBL] [Abstract][Full Text] [Related]
10. Effects of intraperitoneal administration of liposomes and methods of preparing liposomes for local therapy.
Sadzuka Y; Hirama R; Sonobe T
Toxicol Lett; 2002 Jan; 126(2):83-90. PubMed ID: 11751012
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
12. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
13. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
14. Derma roller® microneedles-mediated transdermal delivery of doxorubicin and celecoxib co-loaded liposomes for enhancing the anticancer effect.
Ahmed KS; Shan X; Mao J; Qiu L; Chen J
Mater Sci Eng C Mater Biol Appl; 2019 Jun; 99():1448-1458. PubMed ID: 30889679
[TBL] [Abstract][Full Text] [Related]
15. Increased delivery of doxorubicin into tumor cells using extracellularly activated TAT functionalized liposomes: in vitro and in vivo study.
Yuan W; Kuai R; Ran R; Fu L; Yang Y; Qin Y; Liu Y; Tang J; Fu H; Zhang Q; Yuan M; Zhang Z; Gao F; He Q
J Biomed Nanotechnol; 2014 Aug; 10(8):1563-73. PubMed ID: 25016656
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
[TBL] [Abstract][Full Text] [Related]
17. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
[TBL] [Abstract][Full Text] [Related]
18. Potential cardioprotective and anticancer effects of carvedilol either free or as loaded nanoparticles with or without doxorubicin in solid Ehrlich carcinoma-bearing mice.
Zidan A; El Saadany AA; El Maghraby GM; Abdin AA; Hedya SE
Toxicol Appl Pharmacol; 2023 Apr; 465():116448. PubMed ID: 36921847
[TBL] [Abstract][Full Text] [Related]
19. Coadministration of doxorubicin and etoposide loaded in camel milk phospholipids liposomes showed increased antitumor activity in a murine model.
Maswadeh HM; Aljarbou AN; Alorainy MS; Rahmani AH; Khan MA
Int J Nanomedicine; 2015; 10():2847-55. PubMed ID: 25926730
[TBL] [Abstract][Full Text] [Related]
20. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor.
Mayer LD; Bally MB; Cullis PR; Wilson SL; Emerman JT
Cancer Lett; 1990 Sep; 53(2-3):183-90. PubMed ID: 2208078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
